Patients who are treated with anticoagulant drugs requiring endoscopic biopsy or therapeutics
Conditions
Interventions
None listed
Sponsors
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients taking warfarin or other antigocoagulant drugs (e.g., dabigatran). 2) Patients older than 20 years old. 3) Patients requiring endoscopic biopsy or treatment 4) Patients who gave written informed concent.
Exclusion criteria
Exclusion criteria: 1) Patients with unstable vital sign with high risk of endoscopy. 2) Patients with apparent GI bleeding before endoscopy. 3)Pregnant, breast-feeding women and possibility of pregnancy 4)Patients who will perform endoscopic biopsy and treatment during the same hospitalization period 5)Patients who were considered not suitable to be included in this study by the physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of GI bleeding within one month after the endoscopy or endoscopic treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Duration of hospitalization 2. Prevalence of cardiovascular and cerebro- and systemic vascular events after endoscopy or endoscopic treatment 3. Frequency of requiring re-endoscopy 4. Frequency of massive GI bleeding 5. Frequency of massive GI bleeding threatening life 6. Frequency of cerebrovascular bleeding | — |
Countries
Japan
Contacts
Public ContactHideki Iijima
Osaka University Graduate School of Medicine Department of Gastroenterology and Hepatology
Outcome results
None listed